Sisram Medical reported H1 2026 results showing strong growth in Asia-Pacific markets, offsetting margin pressure in mature Western geographies. The company's device portfolio—including Alma Lasers (diode, alexandrite, Nd:YAG, and RF platforms) and Cutera (Xeo, Secret Pro, Prolite)—continues to drive revenue, though profitability has compressed as competitive pricing and market saturation weigh on gross margins.
Sisram Medical H1 2026: APAC Growth Offsets Margin Pressure
The energy-device maker posts solid interim results as Asia-Pacific expansion compensates for Western margin compression.

| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
APAC growth offsets margin pressure in mature Western markets.
Sisram's geographic pivot toward APAC reflects broader industry dynamics: Western markets are consolidating around a handful of device leaders (InMode, Cutera, Alma), while emerging markets in Asia offer higher growth rates and less price competition. For practice owners in North America and Europe, Sisram's margin pressure is a cautionary signal—device economics are tightening, and practices must optimize utilization and pricing to maintain ROI. Sisram's ability to sustain growth through geographic diversification will determine whether it remains a credible alternative to InMode and Cutera or becomes a regional player.
Source: original report ↗
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.